Prostamax
Synthetic Tetrapeptide | Prostate Bioregulator
On this page
What is Prostamax?
Prostamax is a lab-made four-amino-acid peptide (a tetrapeptide) from the Khavinson bioregulator family, studied mainly in preclinical prostate-tissue research. Animal and cell-culture studies have looked at its effects on prostate-tissue inflammation markers and, separately, on gene-expression changes linked to cellular aging. It's sold here strictly for laboratory research use, not for use in people or animals.
Key terms:
Prostamax is a synthetic tetrapeptide.
Prostamax (Lys-Glu-Asp-Pro, or KEDP) is a lab-made peptide of four amino acids. It belongs to the Khavinson bioregulator family and acts on prostate tissue specifically. Preclinical studies reported anti-inflammatory and tissue-protective effects in chronic prostatitis models. Researchers have also begun looking at epigenetic chromatin regulation (how genes are switched on or off) and longevity applications. Human clinical trial data remains limited.
Key research areas
- Direct systemic delivery
- Optimal bioavailability for prostate tissue targeting
- Established preclinical protocols
Researched dosing
This table reflects the dosing schedules used in preclinical and limited human research on Prostamax, presented as research methodology, not personal usage guidance.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| Prostate studies | 0.5-1mg daily | Once daily | Subcutaneous injection |
| Longevity protocols | 0.75mg daily | Once daily for 10-20 days | Subcutaneous injection |
| Preclinical reference (rat model) | 20 μg/kg | Daily for 15 days | Intramuscular |
Commonly cycled 3 weeks on, 0+ weeks off.
How it works
This section describes how Prostamax is delivered systemically in preclinical research to reach prostate-tissue cells, the dense text below covers delivery route rather than a receptor-level explanation, since detailed cell-signaling data is still limited.
Subcutaneous injection provides systemic circulation for tissue-specific bioregulation of prostate gland cells
Molecular data
These figures, molecular weight, sequence, chain length, are the chemistry ID researchers use to confirm a Prostamax sample's identity; at four amino acids, it's a short bioregulator peptide.
- Weight
- 487.5 Da
- Length
- 4 amino acids
- Type
- Tetrapeptide
Lys-Glu-Asp-Pro (KEDP)
What the studies report
This section lists the research areas, prostate-tissue inflammation markers and cellular-aging gene expression, that animal and cell-culture studies have investigated for Prostamax, a summary of preclinical research, not medical claims about people.
Prostate Health
Preclinical studies show reduced inflammation markers including tissue swelling, vascular hyperemia, and lymphoid infiltration in chronic aseptic prostatitis models. Research demonstrates prevention of sclerotic and atrophic processes that characterize chronic inflammatory prostate conditions. Enhanced proliferative and metabolic activity in prostate epithelial cells and fibroblasts in culture systems.
Longevity
Epigenetic chromatin regulation, Prostamax (KEDP) induces deheterochromatinization in chromatin from elderly subjects, potentially reversing age-related gene silencing.
Immune
Emerging interest in immune modulation through prostate tissue bioregulation and systemic peptide bioregulatory pathways.
Dosage reference
- Doses used in research
- 0.5-1 mg
- Frequency in studies
- Once daily
- Handling
- Reconstituted solution, research use only; not for administration
- Timeline reported in studies
- Effects may take 2-4 weeks to become noticeable; full protocol is 10-20 days
- Storage
- Refrigerate at 2-8°C, use within 14 days
- Cycle length
- 10-20 days
- Break between cycles
- 4-6 month rest periods between cycles
Interactions
This list shows which other longevity- and prostate-research compounds scientists study alongside Prostamax, and why.
Reconstitution & storage
This is the standard laboratory method for turning freeze-dried Prostamax powder into a liquid research solution.
- Remove lyophilized powder from refrigeration and allow to reach room temperature
- Clean vial tops with alcohol swabs and allow to dry completely
- Add 2.0mL bacteriostatic water to achieve 10mg/mL concentration
- Inject water slowly down the side of the vial to minimize foaming
- Gently swirl (do not shake) until powder dissolves completely - solution should be clear
- Store the reconstituted solution refrigerated (2-8°C), labeled with the date and concentration, for laboratory research use only.
Lyophilized: 2-8°C, use within Per manufacturer expiration
Reconstituted: 2-6°C, use within 14 days
Open the Prostamax reconstitution calculatorQuality indicators
These are the visual and documentation checks researchers use to confirm a Prostamax sample is pure and correctly identified before it goes into a study.
White Lyophilized Powder - Prostamax should appear as white to off-white freeze-dried powder indicating proper manufacture
Clear Reconstituted Solution - When properly mixed, solution should be crystal clear with no particles or cloudiness
Certificate of Analysis - Reputable sources provide third-party testing documentation showing 99%+ purity
Research Grade Product - Prostamax is sold as a research peptide - not approved for human consumption in most jurisdictions
Discolored or Clumped Powder - Yellow, brown, or heavily clumped powder indicates degradation or contamination
Cloudy Solution - Persistent cloudiness or precipitates after mixing indicate degraded or contaminated peptide
What to expect
This timeline summarizes what preclinical research has reported at each stage of a study, research context for comparing studies, not a personal-results promise.
Preclinical models reported reduced inflammatory markers at this stage
Enhanced tissue function and cellular activity based on animal studies
Peak effects observed in preclinical research protocols
Safety notes
This section covers handling cautions and regulatory notes for Prostamax, it is not FDA-approved, and published human clinical trial data remains limited compared with its preclinical research base.
- Contraindicated when active prostate malignancy exists - theoretical concern for tumor growth stimulation
- Not recommended during pregnancy or lactation
- Quality sourcing critical - verify purity and avoid contaminated products
- Human clinical trial data not yet published - dosing extrapolated from preclinical models
- Not approved for human consumption in most jurisdictions
Regulatory status
- Not approved by the FDA for any indication.
- Supplied and described for laboratory research use only, not for human or veterinary use.
What is not known
The limits of the published work on Prostamax, stated plainly. Research use only: none of this is guidance for a person.
Two animal studies are widely quoted for this peptide, one on prostate size and one claiming it beat saw palmetto. Neither could be found in any literature search, so this entry does not repeat them. A source nobody can open is not a source.
The work that does exist is about chromatin, the packed form of DNA inside a cell, in cultured cells and tissue pieces. It says nothing about a whole animal or a person.
Most of it is published in a small number of Russian and Georgian journals by overlapping groups, and it has not been repeated elsewhere.
Loosening packed DNA changes what a cell can read. No published work follows that through, so what it means for an animal or a person is not known.
There is no trial in people, no agreed dose, and no safety study of any kind.
The terms, in plain words
Every technical term this page leans on, said again in ordinary words.
- Chromatin
- The packed form DNA takes inside a cell. Packed tight, a gene cannot be read.
- Deheterochromatinization
- Loosening the most tightly packed parts of that packaging, so genes shut away in them can be read again.
- Peptide bioregulator
- The name this line of Russian research gives to its very short peptides. It is a label, not a proven mechanism.
- Explant culture
- A small piece of real tissue kept alive in a dish, part way between cells and an animal.
- Lymphocyte
- A kind of white blood cell, easy to take and so often used in this kind of study.
Sources
The published work behind this entry. Each link was opened and each note says what that paper reports, not what it suggests.
- Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro) Georgian Medical News, 2012Cells from donors aged 75 to 86. The clearest of the chromatin papers. In cell culture only.
- The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats Advances in Gerontology, 2006Tissue pieces from young and old rats. Tests four of these peptides, this one among them, on the tissue each is named for.
- Effects of short peptides on lymphocyte chromatin in senile subjects Bulletin of Experimental Biology and Medicine, 2004The same chromatin finding across five of these peptides in cells from people aged 75 to 88.
How it is studied
In the published studies listed below. Each one names the species it was run in, the dose, how long it ran, and what it reported.
Lymphocyte cultures from donors aged 75 to 86. Reports that the peptide loosened tightly packed chromatin and raised two measures of gene activity compared with untreated cells.
View StudyPieces of prostate, heart, lung and pancreas tissue from young and old rats, grown in culture. Reports more growth in the matching tissue than in the untreated controls.
View Study